## **Core Concept**
Acute hypercalcemia, particularly when caused by malignancy, is a medical emergency that requires prompt treatment. The condition can lead to severe symptoms, including renal failure, bone pain, and neurological symptoms. Agents used to manage hypercalcemia work by either reducing bone resorption, increasing renal excretion of calcium, or decreasing gastrointestinal absorption of calcium.

## **Why the Correct Answer is Right**
Zoledronic acid, a **bisphosphonate**, is considered a first-line treatment for hypercalcemia of malignancy. Bisphosphonates work by inhibiting osteoclast-mediated bone resorption, which is often elevated in malignancy-related hypercalcemia. Zoledronic acid is potent and has a rapid onset of action, making it particularly suitable for acute management.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While hydration and **furosemide** (a loop diuretic) can help manage hypercalcemia by enhancing renal excretion of calcium, they are not as directly effective in reducing bone resorption as bisphosphonates like zoledronic acid.
- **Option B:** **Plicamycin (Mithramycin)** is another agent that can reduce calcium levels by inhibiting bone resorption but is less commonly used today due to its toxicity profile compared to bisphosphonates.
- **Option D:** **Calcitonin** can rapidly lower calcium levels by inhibiting osteoclast activity and enhancing renal excretion of calcium. However, its effect is often less sustained compared to zoledronic acid, and it may not be as effective in severe cases.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **zoledronic acid** is not only effective but also convenient due to its single-dose administration, making it highly suitable for the acute management of hypercalcemia of malignancy. Additionally, ensuring adequate hydration is crucial when treating hypercalcemia, as it helps improve renal function and calcium excretion.

## **Correct Answer:** . Zoledronic acid